… study, we demonstrated that gefitinib and erlotinib appeared to have similar outcomes in
patients … Also, in this study, patients were treated with 250mg/d of gefitinib, and there was no …

… The EGFR-TKIs investigated in this study were gefitinib and erlotinib. Afatinib had not yet
been approved by NHI during the study period. The prescription duration of individual EGFR-…

… Afatinib and gefitinib have also demonstrated efficacy in the first-line treatment of … erlotinib
patients could crossover to receive GP and GP patients could crossover to receive erlotinib. All …

… This study included 71 NSCLC patients who received … This study showed that erlotinib and
gefitinib had similar effectiveness but gefitinib had a better safety profile compared to erlotinib. …

… We conducted a phase II study of erlotinib after failure of gefitinib treatment in patients with
… In our study, of the 15 patients who benefited from gefitinib, two benefited from erlotinib …

… difference in our study. There are somewhat different pharmacological properties between
gefitinib and erlotinib in experi… regardless of the PFS and OS in the current study. Further …

… Thus, in the present study, we investigated the plasma and CSF concentrations of
gefitinib and erlotinib in patients with NSCLC and CNS metastases with EGFR mutations. …

… The study enrolled 96 patients with advanced NSCLC who … Patients receiving gefitinib
and erlotinib had no statistically … receiving erlotinib in our study had received gefitinib before …

… These results show that, although combined EGFR inhibition is a viable strategy for
patients with acquired resistance to erlotinib and gefitinib (with tolerable safety profile), the …

… Patients in this study resumed treatment with the same drug (erlotinib or gefitinib) at the
same … Other investigators have reported responses to erlotinib or gefitinib after patients have …